Woah, this is a default personal text! Edit your profile to change this to what you like!
Solid Member
|
Post by DrSchadenfreude on Jul 29, 2022 11:16:15 GMT -5
Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities
The I-TECH Randomized Clinical Trial
jamanetwork.com/journals/jamainternalmedicine/fullarticle/2789362?guestAccessKey=58760460-df0f-4790-9257-8f3682dca39b&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=021822
February 18, 2022
Key Points
Question Does adding ivermectin, an inexpensive and widely available antiparasitic drug, to the standard of care reduce the risk of severe disease in patients with COVID-19 and comorbidities?
Findings In this open-label randomized clinical trial of high-risk patients with COVID-19 in Malaysia, a 5-day course of oral ivermectin administered during the first week of illness did not reduce the risk of developing severe disease compared with standard of care alone.
Meaning The study findings do not support the use of ivermectin for patients with COVID-19.
Abstract
Importance Ivermectin, an inexpensive and widely available antiparasitic drug, is prescribed to treat COVID-19. Evidence-based data to recommend either for or against the use of ivermectin are needed.
Objective To determine the efficacy of ivermectin in preventing progression to severe disease among high-risk patients with COVID-19.
Design, Setting, and Participants The Ivermectin Treatment Efficacy in COVID-19 High-Risk Patients (I-TECH) study was an open-label randomized clinical trial conducted at 20 public hospitals and a COVID-19 quarantine center in Malaysia between May 31 and October 25, 2021. Within the first week of patients’ symptom onset, the study enrolled patients 50 years and older with laboratory-confirmed COVID-19, comorbidities, and mild to moderate disease.
Interventions Patients were randomized in a 1:1 ratio to receive either oral ivermectin, 0.4 mg/kg body weight daily for 5 days, plus standard of care (n = 241) or standard of care alone (n = 249). The standard of care consisted of symptomatic therapy and monitoring for signs of early deterioration based on clinical findings, laboratory test results, and chest imaging.
Main Outcomes and Measures The primary outcome was the proportion of patients who progressed to severe disease, defined as the hypoxic stage requiring supplemental oxygen to maintain pulse oximetry oxygen saturation of 95% or higher. Secondary outcomes of the trial included the rates of mechanical ventilation, intensive care unit admission, 28-day in-hospital mortality, and adverse events.
Results Among 490 patients included in the primary analysis (mean [SD] age, 62.5 [8.7] years; 267 women [54.5%]), 52 of 241 patients (21.6%) in the ivermectin group and 43 of 249 patients (17.3%) in the control group progressed to severe disease (relative risk [RR], 1.25; 95% CI, 0.87-1.80; P = .25). For all prespecified secondary outcomes, there were no significant differences between groups. Mechanical ventilation occurred in 4 (1.7%) vs 10 (4.0%) (RR, 0.41; 95% CI, 0.13-1.30; P = .17), intensive care unit admission in 6 (2.4%) vs 8 (3.2%) (RR, 0.78; 95% CI, 0.27-2.20; P = .79), and 28-day in-hospital death in 3 (1.2%) vs 10 (4.0%) (RR, 0.31; 95% CI, 0.09-1.11; P = .09). The most common adverse event reported was diarrhea (14 [5.8%] in the ivermectin group and 4 [1.6%] in the control group).
Conclusions and Relevance In this randomized clinical trial of high-risk patients with mild to moderate COVID-19, ivermectin treatment during early illness did not prevent progression to severe disease. The study findings do not support the use of ivermectin for patients with COVID-19.
|
|
Woah, this is a default personal text! Edit your profile to change this to what you like!
Administrator
|
Post by Walter on Jul 29, 2022 11:26:54 GMT -5
Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities
The I-TECH Randomized Clinical Trial
jamanetwork.com/journals/jamainternalmedicine/fullarticle/2789362?guestAccessKey=58760460-df0f-4790-9257-8f3682dca39b&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=021822
February 18, 2022 Key Points Question Does adding ivermectin, an inexpensive and widely available antiparasitic drug, to the standard of care reduce the risk of severe disease in patients with COVID-19 and comorbidities? Findings In this open-label randomized clinical trial of high-risk patients with COVID-19 in Malaysia, a 5-day course of oral ivermectin administered during the first week of illness did not reduce the risk of developing severe disease compared with standard of care alone.
Meaning The study findings do not support the use of ivermectin for patients with COVID-19.
Abstract Importance Ivermectin, an inexpensive and widely available antiparasitic drug, is prescribed to treat COVID-19. Evidence-based data to recommend either for or against the use of ivermectin are needed. Objective To determine the efficacy of ivermectin in preventing progression to severe disease among high-risk patients with COVID-19. Design, Setting, and Participants The Ivermectin Treatment Efficacy in COVID-19 High-Risk Patients (I-TECH) study was an open-label randomized clinical trial conducted at 20 public hospitals and a COVID-19 quarantine center in Malaysia between May 31 and October 25, 2021. Within the first week of patients’ symptom onset, the study enrolled patients 50 years and older with laboratory-confirmed COVID-19, comorbidities, and mild to moderate disease. Interventions Patients were randomized in a 1:1 ratio to receive either oral ivermectin, 0.4 mg/kg body weight daily for 5 days, plus standard of care (n = 241) or standard of care alone (n = 249). The standard of care consisted of symptomatic therapy and monitoring for signs of early deterioration based on clinical findings, laboratory test results, and chest imaging. Main Outcomes and Measures The primary outcome was the proportion of patients who progressed to severe disease, defined as the hypoxic stage requiring supplemental oxygen to maintain pulse oximetry oxygen saturation of 95% or higher. Secondary outcomes of the trial included the rates of mechanical ventilation, intensive care unit admission, 28-day in-hospital mortality, and adverse events. Results Among 490 patients included in the primary analysis (mean [SD] age, 62.5 [8.7] years; 267 women [54.5%]), 52 of 241 patients (21.6%) in the ivermectin group and 43 of 249 patients (17.3%) in the control group progressed to severe disease (relative risk [RR], 1.25; 95% CI, 0.87-1.80; P = .25). For all prespecified secondary outcomes, there were no significant differences between groups. Mechanical ventilation occurred in 4 (1.7%) vs 10 (4.0%) (RR, 0.41; 95% CI, 0.13-1.30; P = .17), intensive care unit admission in 6 (2.4%) vs 8 (3.2%) (RR, 0.78; 95% CI, 0.27-2.20; P = .79), and 28-day in-hospital death in 3 (1.2%) vs 10 (4.0%) (RR, 0.31; 95% CI, 0.09-1.11; P = .09). The most common adverse event reported was diarrhea (14 [5.8%] in the ivermectin group and 4 [1.6%] in the control group). Conclusions and Relevance In this randomized clinical trial of high-risk patients with mild to moderate COVID-19, ivermectin treatment during early illness did not prevent progression to severe disease. The study findings do not support the use of ivermectin for patients with COVID-19. Science...Bah! The hole in that is that Fred never had to find out whether or not IV kept him out of the hospital. Had it progressed to that level, his IV use would have been shown to be useless, but to lessen mild symptoms, it may have some efficacy. That, if fact, is all Fred is claiming, so the study isn't really relevant. |
|
Make America Great Again !!!
Supreme Being-like Member
|
Post by Panama pfRedd on Jul 29, 2022 11:46:06 GMT -5
Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities
The I-TECH Randomized Clinical Trial
jamanetwork.com/journals/jamainternalmedicine/fullarticle/2789362?guestAccessKey=58760460-df0f-4790-9257-8f3682dca39b&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=021822
February 18, 2022 Key Points Question Does adding ivermectin, an inexpensive and widely available antiparasitic drug, to the standard of care reduce the risk of severe disease in patients with COVID-19 and comorbidities? Findings In this open-label randomized clinical trial of high-risk patients with COVID-19 in Malaysia, a 5-day course of oral ivermectin administered during the first week of illness did not reduce the risk of developing severe disease compared with standard of care alone.
Meaning The study findings do not support the use of ivermectin for patients with COVID-19.
Abstract Importance Ivermectin, an inexpensive and widely available antiparasitic drug, is prescribed to treat COVID-19. Evidence-based data to recommend either for or against the use of ivermectin are needed. Objective To determine the efficacy of ivermectin in preventing progression to severe disease among high-risk patients with COVID-19. Design, Setting, and Participants The Ivermectin Treatment Efficacy in COVID-19 High-Risk Patients (I-TECH) study was an open-label randomized clinical trial conducted at 20 public hospitals and a COVID-19 quarantine center in Malaysia between May 31 and October 25, 2021. Within the first week of patients’ symptom onset, the study enrolled patients 50 years and older with laboratory-confirmed COVID-19, comorbidities, and mild to moderate disease. Interventions Patients were randomized in a 1:1 ratio to receive either oral ivermectin, 0.4 mg/kg body weight daily for 5 days, plus standard of care (n = 241) or standard of care alone (n = 249). The standard of care consisted of symptomatic therapy and monitoring for signs of early deterioration based on clinical findings, laboratory test results, and chest imaging. Main Outcomes and Measures The primary outcome was the proportion of patients who progressed to severe disease, defined as the hypoxic stage requiring supplemental oxygen to maintain pulse oximetry oxygen saturation of 95% or higher. Secondary outcomes of the trial included the rates of mechanical ventilation, intensive care unit admission, 28-day in-hospital mortality, and adverse events. Results Among 490 patients included in the primary analysis (mean [SD] age, 62.5 [8.7] years; 267 women [54.5%]), 52 of 241 patients (21.6%) in the ivermectin group and 43 of 249 patients (17.3%) in the control group progressed to severe disease (relative risk [RR], 1.25; 95% CI, 0.87-1.80; P = .25). For all prespecified secondary outcomes, there were no significant differences between groups. Mechanical ventilation occurred in 4 (1.7%) vs 10 (4.0%) (RR, 0.41; 95% CI, 0.13-1.30; P = .17), intensive care unit admission in 6 (2.4%) vs 8 (3.2%) (RR, 0.78; 95% CI, 0.27-2.20; P = .79), and 28-day in-hospital death in 3 (1.2%) vs 10 (4.0%) (RR, 0.31; 95% CI, 0.09-1.11; P = .09). The most common adverse event reported was diarrhea (14 [5.8%] in the ivermectin group and 4 [1.6%] in the control group). Conclusions and Relevance In this randomized clinical trial of high-risk patients with mild to moderate COVID-19, ivermectin treatment during early illness did not prevent progression to severe disease. The study findings do not support the use of ivermectin for patients with COVID-19. Science...Bah! The hole in that is that Fred never had to find out whether or not IV kept him out of the hospital. Had it progressed to that level, his IV use would have been shown to be useless, but to lessen mild symptoms, it may have some efficacy. That, if fact, is all Fred is claiming, so the study isn't really relevant. Fly on, arrogant ass holes. |
|
................................  ................................ = Panama pfRedd - 2021 Regular Season Champion = ...............................  ................................
|
Woah, this is a default personal text! Edit your profile to change this to what you like!
Solid Member
|
Post by DrSchadenfreude on Jul 29, 2022 12:04:30 GMT -5
Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities
The I-TECH Randomized Clinical Trial
jamanetwork.com/journals/jamainternalmedicine/fullarticle/2789362?guestAccessKey=58760460-df0f-4790-9257-8f3682dca39b&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=021822
February 18, 2022 Key Points Question Does adding ivermectin, an inexpensive and widely available antiparasitic drug, to the standard of care reduce the risk of severe disease in patients with COVID-19 and comorbidities? Findings In this open-label randomized clinical trial of high-risk patients with COVID-19 in Malaysia, a 5-day course of oral ivermectin administered during the first week of illness did not reduce the risk of developing severe disease compared with standard of care alone.
Meaning The study findings do not support the use of ivermectin for patients with COVID-19.
Abstract Importance Ivermectin, an inexpensive and widely available antiparasitic drug, is prescribed to treat COVID-19. Evidence-based data to recommend either for or against the use of ivermectin are needed. Objective To determine the efficacy of ivermectin in preventing progression to severe disease among high-risk patients with COVID-19. Design, Setting, and Participants The Ivermectin Treatment Efficacy in COVID-19 High-Risk Patients (I-TECH) study was an open-label randomized clinical trial conducted at 20 public hospitals and a COVID-19 quarantine center in Malaysia between May 31 and October 25, 2021. Within the first week of patients’ symptom onset, the study enrolled patients 50 years and older with laboratory-confirmed COVID-19, comorbidities, and mild to moderate disease. Interventions Patients were randomized in a 1:1 ratio to receive either oral ivermectin, 0.4 mg/kg body weight daily for 5 days, plus standard of care (n = 241) or standard of care alone (n = 249). The standard of care consisted of symptomatic therapy and monitoring for signs of early deterioration based on clinical findings, laboratory test results, and chest imaging. Main Outcomes and Measures The primary outcome was the proportion of patients who progressed to severe disease, defined as the hypoxic stage requiring supplemental oxygen to maintain pulse oximetry oxygen saturation of 95% or higher. Secondary outcomes of the trial included the rates of mechanical ventilation, intensive care unit admission, 28-day in-hospital mortality, and adverse events. Results Among 490 patients included in the primary analysis (mean [SD] age, 62.5 [8.7] years; 267 women [54.5%]), 52 of 241 patients (21.6%) in the ivermectin group and 43 of 249 patients (17.3%) in the control group progressed to severe disease (relative risk [RR], 1.25; 95% CI, 0.87-1.80; P = .25). For all prespecified secondary outcomes, there were no significant differences between groups. Mechanical ventilation occurred in 4 (1.7%) vs 10 (4.0%) (RR, 0.41; 95% CI, 0.13-1.30; P = .17), intensive care unit admission in 6 (2.4%) vs 8 (3.2%) (RR, 0.78; 95% CI, 0.27-2.20; P = .79), and 28-day in-hospital death in 3 (1.2%) vs 10 (4.0%) (RR, 0.31; 95% CI, 0.09-1.11; P = .09). The most common adverse event reported was diarrhea (14 [5.8%] in the ivermectin group and 4 [1.6%] in the control group). Conclusions and Relevance In this randomized clinical trial of high-risk patients with mild to moderate COVID-19, ivermectin treatment during early illness did not prevent progression to severe disease. The study findings do not support the use of ivermectin for patients with COVID-19. Science...Bah! The hole in that is that Fred never had to find out whether or not IV kept him out of the hospital. Had it progressed to that level, his IV use would have been shown to be useless, but to lessen mild symptoms, it may have some efficacy. That, if fact, is all Fred is claiming, so the study isn't really relevant. What Fred doesn't understand is that we can't really prove the efficacy of any particular medication without properly randomized controls. I'm glad Fred is recovering from COVID, probably Omicron BA.5, but his recovery doesn't prove that horse paste was efficacious. He might have recovered just as well while taking 50 mg MAGA capsules of Donald Trump's feces (at a cost of only $10 per capsule.) |
|
Woah, this is a default personal text! Edit your profile to change this to what you like!
Administrator
|
Post by Walter on Jul 29, 2022 13:44:43 GMT -5
Science...Bah! The hole in that is that Fred never had to find out whether or not IV kept him out of the hospital. Had it progressed to that level, his IV use would have been shown to be useless, but to lessen mild symptoms, it may have some efficacy. That, if fact, is all Fred is claiming, so the study isn't really relevant. What Fred doesn't understand is that we can't really prove the efficacy of any particular medication without properly randomized controls. I'm glad Fred is recovering from COVID, probably Omicron BA.5, but his recovery doesn't prove that horse paste was efficacious. He might have recovered just as well while taking 50 mg MAGA capsules of Donald Trump's feces (at a cost of only $10 per capsule.) Of course. All true. But he thinks it helped, there is some data that it helps some symptoms, and I haven't seen any data that it hurts anything, so let him believe whatever wants as long as he gets well. |
|
Make America Great Again !!!
Supreme Being-like Member
|
Post by Panama pfRedd on Jul 29, 2022 13:50:25 GMT -5
Most of us here have no interest in what you or your twin have to say.
|
|
................................ ................................ = Panama pfRedd - 2021 Regular Season Champion = ............................... ................................
|
Woah, this is a default personal text! Edit your profile to change this to what you like!
Solid Member
|
Post by DrSchadenfreude on Jul 29, 2022 14:33:42 GMT -5
Most of us here have no interest in what you or your twin have to say. Most of you Trump loons have no interest in reality. That's why you support Trump and take horse paste. |
|
Woah, this is a default personal text! Edit your profile to change this to what you like!
Member with solid, if unspectacular number of posts
|
Post by Coaltrain on Jul 29, 2022 17:16:50 GMT -5
Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities
The I-TECH Randomized Clinical Trial
jamanetwork.com/journals/jamainternalmedicine/fullarticle/2789362?guestAccessKey=58760460-df0f-4790-9257-8f3682dca39b&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=021822
February 18, 2022 Key Points Question Does adding ivermectin, an inexpensive and widely available antiparasitic drug, to the standard of care reduce the risk of severe disease in patients with COVID-19 and comorbidities? Findings In this open-label randomized clinical trial of high-risk patients with COVID-19 in Malaysia, a 5-day course of oral ivermectin administered during the first week of illness did not reduce the risk of developing severe disease compared with standard of care alone.
Meaning The study findings do not support the use of ivermectin for patients with COVID-19.
Abstract Importance Ivermectin, an inexpensive and widely available antiparasitic drug, is prescribed to treat COVID-19. Evidence-based data to recommend either for or against the use of ivermectin are needed. Objective To determine the efficacy of ivermectin in preventing progression to severe disease among high-risk patients with COVID-19. Design, Setting, and Participants The Ivermectin Treatment Efficacy in COVID-19 High-Risk Patients (I-TECH) study was an open-label randomized clinical trial conducted at 20 public hospitals and a COVID-19 quarantine center in Malaysia between May 31 and October 25, 2021. Within the first week of patients’ symptom onset, the study enrolled patients 50 years and older with laboratory-confirmed COVID-19, comorbidities, and mild to moderate disease. Interventions Patients were randomized in a 1:1 ratio to receive either oral ivermectin, 0.4 mg/kg body weight daily for 5 days, plus standard of care (n = 241) or standard of care alone (n = 249). The standard of care consisted of symptomatic therapy and monitoring for signs of early deterioration based on clinical findings, laboratory test results, and chest imaging. Main Outcomes and Measures The primary outcome was the proportion of patients who progressed to severe disease, defined as the hypoxic stage requiring supplemental oxygen to maintain pulse oximetry oxygen saturation of 95% or higher. Secondary outcomes of the trial included the rates of mechanical ventilation, intensive care unit admission, 28-day in-hospital mortality, and adverse events. Results Among 490 patients included in the primary analysis (mean [SD] age, 62.5 [8.7] years; 267 women [54.5%]), 52 of 241 patients (21.6%) in the ivermectin group and 43 of 249 patients (17.3%) in the control group progressed to severe disease (relative risk [RR], 1.25; 95% CI, 0.87-1.80; P = .25). For all prespecified secondary outcomes, there were no significant differences between groups. Mechanical ventilation occurred in 4 (1.7%) vs 10 (4.0%) (RR, 0.41; 95% CI, 0.13-1.30; P = .17), intensive care unit admission in 6 (2.4%) vs 8 (3.2%) (RR, 0.78; 95% CI, 0.27-2.20; P = .79), and 28-day in-hospital death in 3 (1.2%) vs 10 (4.0%) (RR, 0.31; 95% CI, 0.09-1.11; P = .09). The most common adverse event reported was diarrhea (14 [5.8%] in the ivermectin group and 4 [1.6%] in the control group). Conclusions and Relevance In this randomized clinical trial of high-risk patients with mild to moderate COVID-19, ivermectin treatment during early illness did not prevent progression to severe disease. The study findings do not support the use of ivermectin for patients with COVID-19. Science...Bah! The hole in that is that Fred never had to find out whether or not IV kept him out of the hospital. Had it progressed to that level, his IV use would have been shown to be useless, but to lessen mild symptoms, it may have some efficacy. That, if fact, is all Fred is claiming, so the study isn't really relevant. In this case, Walt, I agree with you. The case study that Doc Crude is talking about is pure BS. There are thousands that have taken Ivermectin and have been spared. My Brother in law was one. He almost died when Covid took over his lungs and made one colapse. However, I also know of 2 people that have never had a single vaccine, have gotten this omnicron and were over it, in less than 36 hours. Guess it has to do with how strong a person's immune system really is. |
|
|
Don't like guns?
Don't buy one.
There, wasn't that easy!
|
Woah, this is a default personal text! Edit your profile to change this to what you like!
Godlike Member
|
Post by cbisbig on Jul 29, 2022 20:14:54 GMT -5
Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities
The I-TECH Randomized Clinical Trial
jamanetwork.com/journals/jamainternalmedicine/fullarticle/2789362?guestAccessKey=58760460-df0f-4790-9257-8f3682dca39b&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=021822
February 18, 2022 Key Points Question Does adding ivermectin, an inexpensive and widely available antiparasitic drug, to the standard of care reduce the risk of severe disease in patients with COVID-19 and comorbidities? Findings In this open-label randomized clinical trial of high-risk patients with COVID-19 in Malaysia, a 5-day course of oral ivermectin administered during the first week of illness did not reduce the risk of developing severe disease compared with standard of care alone.
Meaning The study findings do not support the use of ivermectin for patients with COVID-19.
Abstract Importance Ivermectin, an inexpensive and widely available antiparasitic drug, is prescribed to treat COVID-19. Evidence-based data to recommend either for or against the use of ivermectin are needed. Objective To determine the efficacy of ivermectin in preventing progression to severe disease among high-risk patients with COVID-19. Design, Setting, and Participants The Ivermectin Treatment Efficacy in COVID-19 High-Risk Patients (I-TECH) study was an open-label randomized clinical trial conducted at 20 public hospitals and a COVID-19 quarantine center in Malaysia between May 31 and October 25, 2021. Within the first week of patients’ symptom onset, the study enrolled patients 50 years and older with laboratory-confirmed COVID-19, comorbidities, and mild to moderate disease. Interventions Patients were randomized in a 1:1 ratio to receive either oral ivermectin, 0.4 mg/kg body weight daily for 5 days, plus standard of care (n = 241) or standard of care alone (n = 249). The standard of care consisted of symptomatic therapy and monitoring for signs of early deterioration based on clinical findings, laboratory test results, and chest imaging. Main Outcomes and Measures The primary outcome was the proportion of patients who progressed to severe disease, defined as the hypoxic stage requiring supplemental oxygen to maintain pulse oximetry oxygen saturation of 95% or higher. Secondary outcomes of the trial included the rates of mechanical ventilation, intensive care unit admission, 28-day in-hospital mortality, and adverse events. Results Among 490 patients included in the primary analysis (mean [SD] age, 62.5 [8.7] years; 267 women [54.5%]), 52 of 241 patients (21.6%) in the ivermectin group and 43 of 249 patients (17.3%) in the control group progressed to severe disease (relative risk [RR], 1.25; 95% CI, 0.87-1.80; P = .25). For all prespecified secondary outcomes, there were no significant differences between groups. Mechanical ventilation occurred in 4 (1.7%) vs 10 (4.0%) (RR, 0.41; 95% CI, 0.13-1.30; P = .17), intensive care unit admission in 6 (2.4%) vs 8 (3.2%) (RR, 0.78; 95% CI, 0.27-2.20; P = .79), and 28-day in-hospital death in 3 (1.2%) vs 10 (4.0%) (RR, 0.31; 95% CI, 0.09-1.11; P = .09). The most common adverse event reported was diarrhea (14 [5.8%] in the ivermectin group and 4 [1.6%] in the control group). Conclusions and Relevance In this randomized clinical trial of high-risk patients with mild to moderate COVID-19, ivermectin treatment during early illness did not prevent progression to severe disease. The study findings do not support the use of ivermectin for patients with COVID-19. Epub 2020 Dec 2. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness |
|
|
ROLL TIDE!
29 SEC Championships
18 National Championships
2015-16 Bowl Champion Douche
2020 Pandemic Bowl Champ
|
Make America Great Again !!!
Supreme Being-like Member
|
Post by Panama pfRedd on Jul 29, 2022 20:20:19 GMT -5
Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities
The I-TECH Randomized Clinical Trial
jamanetwork.com/journals/jamainternalmedicine/fullarticle/2789362?guestAccessKey=58760460-df0f-4790-9257-8f3682dca39b&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=021822
February 18, 2022 Key Points Question Does adding ivermectin, an inexpensive and widely available antiparasitic drug, to the standard of care reduce the risk of severe disease in patients with COVID-19 and comorbidities? Findings In this open-label randomized clinical trial of high-risk patients with COVID-19 in Malaysia, a 5-day course of oral ivermectin administered during the first week of illness did not reduce the risk of developing severe disease compared with standard of care alone.
Meaning The study findings do not support the use of ivermectin for patients with COVID-19.
Abstract Importance Ivermectin, an inexpensive and widely available antiparasitic drug, is prescribed to treat COVID-19. Evidence-based data to recommend either for or against the use of ivermectin are needed. Objective To determine the efficacy of ivermectin in preventing progression to severe disease among high-risk patients with COVID-19. Design, Setting, and Participants The Ivermectin Treatment Efficacy in COVID-19 High-Risk Patients (I-TECH) study was an open-label randomized clinical trial conducted at 20 public hospitals and a COVID-19 quarantine center in Malaysia between May 31 and October 25, 2021. Within the first week of patients’ symptom onset, the study enrolled patients 50 years and older with laboratory-confirmed COVID-19, comorbidities, and mild to moderate disease. Interventions Patients were randomized in a 1:1 ratio to receive either oral ivermectin, 0.4 mg/kg body weight daily for 5 days, plus standard of care (n = 241) or standard of care alone (n = 249). The standard of care consisted of symptomatic therapy and monitoring for signs of early deterioration based on clinical findings, laboratory test results, and chest imaging. Main Outcomes and Measures The primary outcome was the proportion of patients who progressed to severe disease, defined as the hypoxic stage requiring supplemental oxygen to maintain pulse oximetry oxygen saturation of 95% or higher. Secondary outcomes of the trial included the rates of mechanical ventilation, intensive care unit admission, 28-day in-hospital mortality, and adverse events. Results Among 490 patients included in the primary analysis (mean [SD] age, 62.5 [8.7] years; 267 women [54.5%]), 52 of 241 patients (21.6%) in the ivermectin group and 43 of 249 patients (17.3%) in the control group progressed to severe disease (relative risk [RR], 1.25; 95% CI, 0.87-1.80; P = .25). For all prespecified secondary outcomes, there were no significant differences between groups. Mechanical ventilation occurred in 4 (1.7%) vs 10 (4.0%) (RR, 0.41; 95% CI, 0.13-1.30; P = .17), intensive care unit admission in 6 (2.4%) vs 8 (3.2%) (RR, 0.78; 95% CI, 0.27-2.20; P = .79), and 28-day in-hospital death in 3 (1.2%) vs 10 (4.0%) (RR, 0.31; 95% CI, 0.09-1.11; P = .09). The most common adverse event reported was diarrhea (14 [5.8%] in the ivermectin group and 4 [1.6%] in the control group). Conclusions and Relevance In this randomized clinical trial of high-risk patients with mild to moderate COVID-19, ivermectin treatment during early illness did not prevent progression to severe disease. The study findings do not support the use of ivermectin for patients with COVID-19. Epub 2020 Dec 2. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness I'm ending my treatment after only 3 days. I'm damn near back to normal already, and I was really damn sick for the first two days. Ask wolly how long his recovery is taking, being that he's fully "vaxxed", "boosted" and all. |
|
................................ ................................ = Panama pfRedd - 2021 Regular Season Champion = ............................... ................................
|
Woah, this is a default personal text! Edit your profile to change this to what you like!
Godlike Member
|
Post by cbisbig on Jul 29, 2022 20:21:57 GMT -5
I'm ending my treatment after only 3 days. I'm damn near back to normal already, and I was really damn sick for the first two days. Ask wolly how long his recovery is taking, being that he's fully "vaxxed", "boosted" and all. It will be more than 3 days guaranteed |
|
|
ROLL TIDE!
29 SEC Championships
18 National Championships
2015-16 Bowl Champion Douche
2020 Pandemic Bowl Champ
|
Make America Great Again !!!
Supreme Being-like Member
|
Post by Panama pfRedd on Jul 29, 2022 21:30:03 GMT -5
I'm ending my treatment after only 3 days. I'm damn near back to normal already, and I was really damn sick for the first two days. Ask wolly how long his recovery is taking, being that he's fully "vaxxed", "boosted" and all. It will be more than 3 days guaranteed Well we know it's at least a week because he said I should count on a shitty week because his fever lasted over a week and still coughing. Well, I only had fever for two days but still coughing a bit on day 3. Two days unvaxxed with IV is a far cry from more that a week and counting fully vaxxed/boosted and a repeat infection. But I'm the dumb one. Go figure. |
|
................................ ................................ = Panama pfRedd - 2021 Regular Season Champion = ............................... ................................
|
Woah, this is a default personal text! Edit your profile to change this to what you like!
Solid Member
|
Post by DrSchadenfreude on Jul 29, 2022 23:15:45 GMT -5
It will be more than 3 days guaranteed Well we know it's at least a week because he said I should count on a shitty week because his fever lasted over a week and still coughing. Well, I only had fever for two days but still coughing a bit on day 3. Two days unvaxxed with IV is a far cry from more that a week and counting fully vaxxed/boosted and a repeat infection. But I'm the dumb one. Go figure. Why do you assume that your vulnerability to the virus is comparable to Walter's? There are a lot of variables that influence a person's vulnerability to a particular pathogen-- including genetic factors, age, immune status, medical conditions, local air quality, etc. And what a truly wretched human being you are! First you present with understandable fear and distress about symptoms of a potentially serious illness, and people wish you well. Then, as soon as you begin to recover from your illness, you promptly resume your vile insults toward your well wishers. I don't know what happened to you in your family of origin, but it must have been some weird shit. Did your brother give you a lot of swirlies when you were a kid, or what?  |
|
Woah, this is a default personal text! Edit your profile to change this to what you like!
Administrator
|
Post by Walter on Jul 30, 2022 6:55:35 GMT -5
It will be more than 3 days guaranteed Well we know it's at least a week because he said I should count on a shitty week because his fever lasted over a week and still coughing. Well, I only had fever for two days but still coughing a bit on day 3. Two days unvaxxed with IV is a far cry from more that a week and counting fully vaxxed/boosted and a repeat infection. But I'm the dumb one. Go figure. You weren't on immune-suppression drugs as I was, so comparisons are not particularly valid. Judging by fever alone, six days for me with about 4-5 days of feeling rotten. |
|
Make America Great Again !!!
Supreme Being-like Member
|
Post by Panama pfRedd on Jul 30, 2022 8:30:15 GMT -5
Well we know it's at least a week because he said I should count on a shitty week because his fever lasted over a week and still coughing. Well, I only had fever for two days but still coughing a bit on day 3. Two days unvaxxed with IV is a far cry from more that a week and counting fully vaxxed/boosted and a repeat infection. But I'm the dumb one. Go figure. You weren't on immune-suppression drugs as I was, so comparisons are not particularly valid. Judging by fever alone, six days for me with about 4-5 days of feeling rotten. Glad your feeling better and getting back to 'normal'. |
|
................................ ................................ = Panama pfRedd - 2021 Regular Season Champion = ............................... ................................
|
